Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap361.28M
Enterprise Value327.51M
LCTX
(NYSEAMERICAN)Lineage Cell Therapeutics, Inc.
$1.57-- (--)
Loading... - Market loading
Lineage Cell Therapeutics (LCTX) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)25.14
Forward Price/Sales16.40
Price/Book (mrq)8.21
Price/Tangible Book (mrq)168.07
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue22.50
EV/Earnings-5.15
EV/EBITDA67.03
EV/EBIT-16.10
EV/FCF-17.10
Stock Price
Current price, 52-week range, and moving averages
Current Price$1.57
1-Day Change0.63%
52-Week High$2.09
52-Week Low$0.37
52-Week Change286.86%
YTD Change-3.05%
1-Year Change263.68%
50-Day MA$1.68
200-Day MA$1.50
Avg Volume (30 day)581.55K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding230.12M
Book Value per Share$0.19
Net Cash per Share$0.17
FCF per Share$-0.08
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$5.33
Target Upside/Downside239.49%
Analyst ConsensusBuy
Analyst Count3
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin94.19%
EBITDA Margin (ttm)33.57%
EBIT Margin (ttm)-139.74%
Operating Margin (ttm)-47.67%
Pretax Margin (ttm)-471.61%
Profit Margin (ttm)-436.47%
FCF Margin (ttm)-131.58%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-142.61%
Return on Assets (ttm)-56.43%
Return on Invested Capital (ttm)-260.15%
Return on Capital Employed (ttm)-20.10%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue14.56M
Gross Profit13.71M
Operating Income-6.94M
Pretax Income-68.65M
Net Income-63.53M
EBITDA4.89M
EBIT-20.34M
Diluted EPS$-0.28
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-18.92M
Capital Expenditures234.00K
Free Cash Flow-19.15M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth53.24%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)112.58M
Cash & Securities (mrq)40.79M
Net Cash (mrq)39.94M
Net Cash per Share$0.17
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)2.42M
Working Capital (mrq)47.79M
Total Equity (mrq)44.55M
Book Value per Share$0.19
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)5.20
Quick Ratio (mrq)5.20
Debt/Equity (mrq)0.05
Debt/EBITDA (ttm)0.50
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Ex-Dividend DateDec 15, 2003
Pay DateDec 15, 2003
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-17.36%
FCF Yield-5.23%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-2.59
Piotroski F-Score3/9
Frequently Asked Questions About Lineage Cell Therapeutics Statistics
What are the key financial metrics for LCTX?
Lineage Cell Therapeutics, Inc. (LCTX) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is LCTX's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Lineage Cell Therapeutics is overvalued or undervalued.
How do I read LCTX's profitability ratios?
Lineage Cell Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do LCTX's debt ratios indicate?
The financial health section shows Lineage Cell Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is LCTX's dividend analysis?
The dividend section covers Lineage Cell Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.